MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

Vaccine

Volumn 25, Issue 9, 2007, Pages 1607-1618

  Mukherjee, P ^a   Pathangey, L B ^a   Bradley, J B ^a   Tinder, T L ^a   Basu, G D ^a   Akporiaye, E T ^b   Gendler, S J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Colon cancer; CpG ODN; GM CSF; MUC1

Indexed keywords

ALANYLPROLYLGLYCYLSERYLTHREONYLALANYLPROLYLPROLYLALANINE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MUCIN 1; SERYLALANYLPROLYLASPARTYLTHREONYLARGINYLPROLYLALANYLPROLINE; THREONYLPROLYLPROLYLALANYLTYROSYLARGINYLPROLYLPROLYLASPARAGINYLALANYL PROLYLISOLEUCYLLEUCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG TOLERANCE; HELPER CELL; HOST; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

ANIMALS; CA-15-3 ANTIGEN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MUCINS; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33846194189     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.007     Document Type: Article

References (67)

1. Zotter S., Hageman P.C., Lossnitzer A., Mooi W.J., and Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12 (1988) 55-101
2. Croce M.V., Isla-Larrain M.T., Rua C.E., Rabassa M.E., Gendler S.J., and Segal-Eiras A. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. J Histochem Cytochem 51 6 (2003) 781-788
3. Girling A., Bartkova J., Burchell J., Gendler S., Gillet C., and Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 43 (1989) 1072-1076
4. Domenech N., Henderson R.A., and Finn O.J. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155 10 (1995) 4766-4774
5. Agrawal B., Reddish M.A., and Longenecker B.M. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157 5 (1996) 2089-2095
6. Apostolopoulos V., Haurum J.S., and McKenzie I.F.C. Muc1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 27 10 (1997) 2579-2587
7. Apostolopoulos V., Karanikas V., Haurum J.S., and McKenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159 11 (1997) 5211-5218
8. Reddish M., MacLean G.D., Koganty R.R., Kan-Mitchell J., Jones V., Mitchell M.S., et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76 6 (1998) 817-823
9. Mukherjee P., Ginardi A.R., Madsen C.S., Sterner C.J., Adriance M.C., Tevethia M.J., et al. Mice with spontaneous pancreatic cancer naturally develop MUC1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol 165 6 (2000) 3451-3460
10. Mukherjee P., Madsen C.S., Ginardi A.R., Tinder T.L., Jacobs F., Parker J., et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26 1 (2003) 47-62
11. Mukherjee P., Ginardi A.R., Tinder T.L., Sterner C.J., and Gendler S.J. MUC1-specific CTLs eradicate tumors when adoptively transferred in vivo. Clin Cancer Res 7 (2003) 848s-855s
12. North S.A., Graham K., Bodnar D., and Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 176 1 (2006) 91-95
13. Kohlgraf K.G., Gawron A.J., Higashi M., Meza J.L., Burdick M.D., Kitajima S., et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63 16 (2003) 5011-5020
14. Ramanathan R.K., Lee K.M., McKolanis J., Hitbold E., Schraut W., Moser A.J., et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54 3 (2005) 254-264
15. Treon S.P., Mollick J.A., Urashima M., Teoh G., Chauhan D., Ogata A., et al. MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93 4 (1999) 1287-1298
16. Brossart P., Schneider A., Dill P., Schammann T., Grunebach F., Wirths S., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61 18 (2001) 6846-6850
17. Loveland B.E., Zhao A., White S., Gan H., Hamilton K., Xing P.X., et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12 3 Pt 1 (2006) 869-877
18. Apostolopoulos V., Pietersz G.A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B.E., et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 8 3 (2006) R27
19. Pantuck A.J., van Ophoven A., Gitlitz B.J., Tso C.L., Acres B., Squiban P., et al. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27 3 (2004) 240-253
20. North S., and Butts C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 4 3 (2005) 249-257
21. Pecher G., Haring A., Kaiser L., and Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 51 11-12 (2002) 669-673
22. Kontani K., Taguchi O., Ozaki Y., Hanaoka J., Sawai S., Inoue S., et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 12 4 (2003) 493-502
23. Scholl S., Squiban P., Bizouarne N., Baudin M., Acres B., Von Mensdorff-Pouilly S., et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003 3 (2003) 194-201
24. Snyder L.A., Goletz T.J., Gunn G.R., Shi F.F., Harris M.C., Cochlin K., et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24 16 (2006) 3340-3352
25. Brossart P., Heinrich K.S., Stuhler G., Behnke L., Reichardt V.L., Stevanovic S., et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93 12 (1999) 4309-4317
26. Heukamp L.C., van der Burg S.H., Drijfhout J.W., Melief C.J., Taylor-Papadimitriou J., and Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91 3 (2001) 385-392
27. Tsang K.Y., Palena C., Gulley J., Arlen P., and Schlom J. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 10 6 (2004) 2139-2149
28. Wierecky J., Mueller M., and Brossart P. Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55 1 (2006) 63-67
29. Wierecky J., Muller M.R., Wirths S., Halder-Oehler E., Dorfel D., Schmidt S.M., et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66 11 (2006) 5910-5918
30. Knutson K.L., and Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54 8 (2005) 721-728
31. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
32. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
33. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 6 (2006) 471-484
34. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Waldschmidt M., et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167 9 (2001) 4878-4886
35. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169 7 (2002) 3892-3899
36. Milas L., Mason K.A., Ariga H., Hunter N., Neal R., Valdecanas D., et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64 15 (2004) 5074-5077
37. Brunner C., Seiderer J., Schlamp A., Bidlingmaier M., Eigler A., Haimerl W., et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165 11 (2000) 6278-6286
38. Schneeberger A., Wagner C., Zemann A., Luhrs P., Kutil R., Goos M., et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 123 2 (2004) 371-379
39. Bourquin C., Schreiber S., Beck S., Hartmann G., and Endres S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. Int J Cancer 118 11 (2006) 2790-2795
40. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6 2 (2004) 88-95
41. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
42. Jones T., Stern A., and Lin R. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 13 Suppl. 2 (1994) S47-S53
43. Jager E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jager D., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67 1 (1996) 54-62
44. Fagerberg J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 13 3 (1996) 155-160
45. Carlsson T., and Struve J. Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine [letter]. Infection 25 2 (1997) 129
46. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13 (1995) 399-415
47. Golumbek P.T., Azhari R., Jaffee E.M., Levitsky H.I., Lazenby A., Leong K., et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53 24 (1993) 5841-5844
48. Markovic S.N., Suman V.J., Ingle J.N., Kaur J.S., Pitot H.C., Loprinzi C.L., et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 29 4 (2006) 352-360
49. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88 1 (1996) 202-210
50. Kaplan C., Morel-Kopp M.C., Verdy E., Pron B., and Tchernia G. Fetal and neonatal immune thrombocytopenias. Study group "mother-child immune thrombopenias". Presse Med 21 36 (1992) 1717-1724
51. Rowse G.J., Tempero R.M., VanLith M.L., Hollingsworth M.A., and Gendler S.J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58 (1998) 315-321
52. Franco A., Yokoyama T., Huynh D., Thomson C., Nathenson S.G., and Grey H.M. Fine specificity and MHC restriction of trinitrophenyl-specific CTL. J Immunol 162 6 (1999) 3388-3394
53. Simpson-Herrerns L., and Lloyd H.H. Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemother Rep 54 (1970) 143-174
54. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176 6 (1992) 1693-1702
55. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 168 3 (2002) 1212-1218
56. Davila E., and Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol 165 1 (2000) 539-547
57. Davila E., Velez M.G., Heppelmann C.J., and Celis E. Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood 100 7 (2002) 2537-2545
58. Finn O. History of tumour vaccines and novel approaches for preventive cancer vaccines. Dev Biol (Basel) 116 (2004) 3-12
59. Finn O.J. Tumor immunology at the service of cancer immunotherapy. Curr Opin Immunol 16 2 (2004) 127-129
60. Finn O.J. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3 8 (2003) 630-641
61. Pure E., Allison J.P., and Schreiber R.D. Breaking down the barriers to cancer immunotherapy. Nat Immunol 6 12 (2005) 1207-1210
62. Springer G.F. T and Tn, general carcinoma autoantigens. Science 224 4654 (1984) 1198-1206
63. Muller S., and Hanisch F.G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem 277 29 (2002) 26103-26112
64. Xu Y., Gendler S.J., and Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 199 5 (2004) 707-716
65. Sidney J., Grey H.M., Kubo R.T., and Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17 6 (1996) 261-266
66. Vlad A.M., Muller S., Cudic M., Paulsen H., Otvos Jr. L., Hanisch F.G., et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196 11 (2002) 1435-1446
67. Apostolopoulos V., Yuriev E., Ramsland P.A., Halton J., Osinski C., Li W., et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 100 25 (2003) 15029-15034